Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Scott N Dean & Monique L van Hoek. (2015) Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida. Virulence 6:5, pages 487-503.
Read now
Read now
Z. Sanad, H. Ellakwa & B. Desouky. (2011) Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. Climacteric 14:3, pages 369-377.
Read now
Read now
Joel Jules, Jason W Ashley & Xu Feng. (2010) Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opinion on Therapeutic Targets 14:9, pages 923-934.
Read now
Read now
Enrico M Messalli & Cono Scaffa. (2009) Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. International Journal of Women's Health 1, pages 11-20.
Read now
Read now
Articles from other publishers (20)
Wei Cong, Huaxing Shen, Xiufei Liao, Mengjun Zheng, Xianglong Kong, Zhe Wang, Si Chen, Yulei Li, Honggang Hu & Xiang Li. (2023) Discovery of an orally effective double-stapled peptide for reducing ovariectomy-induced bone loss in mice. Acta Pharmaceutica Sinica B.
Crossref
Crossref
Xiu-Feng Tang, Zi-Tong Ma, Ying-Ying Gao, Han Wang, Xiao-Xi Li, Ping Yu & Ren-Hui Liu. (2020) Systemic osteoprotective effects of Epimedii Folium and Ligustri Lucidi Fructus in senile osteoporosis rats by promoting the osteoblastogenesis and osteoclastogenesis based on MLP-ANN model. Chinese Medicine 15:1.
Crossref
Crossref
Tairong Liu, Wei Cong, Lei Ye, Xike Xu, Xiufei Liao, Gang Xie, Zhaoxi Cheng, Honggang Hu, Xiang Li & Hongli Liao. (2020) Rational design of stapled peptides targeting phosphorylated GSK3β for regulating osteoclast differentiation. RSC Advances 10:13, pages 7758-7763.
Crossref
Crossref
Dongfeng Zhao, Qiang Wang, Yongjian Zhao, Hao Zhang, Nannan Sha, Dezhi Tang, Shufen Liu, Sheng Lu, Qi Shi, Yan Zhang, Yufeng DongYongjun Wang & Bing Shu. (2018) The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice. Menopause 25:12, pages 1459-1469.
Crossref
Crossref
Qiang Wang, Yongjian Zhao, Nannan Sha, Yan Zhang, Chenguang Li, Hao Zhang, Dezhi Tang, Sheng Lu, Qi Shi, Yongjun Wang, Bing Shu & Dongfeng Zhao. (2018) The systemic bone protective effects of Gushukang granules in ovariectomized mice by inhibiting osteoclastogenesis and stimulating osteoblastogenesis. Journal of Pharmacological Sciences 136:3, pages 155-164.
Crossref
Crossref
Ashraf Abdel-Naim, Abdullah Alghamdi, Mardi Algandaby, Fahad Al-Abbasi, Ahmed Al-Abd, Hossam Abdallah, Ali El-Halawany & Masao Hattori. (2017) Phenolics Isolated from Aframomum meleguta Enhance Proliferation and Ossification Markers in Bone Cells. Molecules 22:9, pages 1467.
Crossref
Crossref
Sebastian Mirkin & James H. Pickar. (2015) Selective estrogen receptor modulators (SERMs): A review of clinical data. Maturitas 80:1, pages 52-57.
Crossref
Crossref
Colin G. Miller, Hui Jing Yu & Cornelis van Kuijk. 2014. Medical Imaging in Clinical Trials. Medical Imaging in Clinical Trials
237
251
.
Jason W. AshleyErin M. McCoyDaniel A. ClementsZhenqi ShiTaosheng ChenXu Feng. (2011) Development of Cell-Based High-Throughput Assays for the Identification of Inhibitors of Receptor Activator of Nuclear Factor-Kappa B Signaling. ASSAY and Drug Development Technologies 9:1, pages 40-49.
Crossref
Crossref
Charles H. ChesnutIIIIII & Moise Azria. 2010. Osteoporosis. Osteoporosis
423
441
.
C. H. ChesnutIIIIII, M. Azria, S. Silverman, M. Engelhardt, M. Olson & L. Mindeholm. (2007) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International 19:4, pages 479-491.
Crossref
Crossref
Jun IwamotoYoshihiro SatoMitsuyoshi UzawaTsuyoshi TakedaHideo Matsumoto. (2008) Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis. Yonsei Medical Journal 49:1, pages 119.
Crossref
Crossref
Robert R. Recker, David Kendler, Christopher P. Recknor, Theodore W. Rooney, E. Michael Lewiecki, Wulf H. Utian, Jane A. Cauley, Joanne Lorraine, Yongming Qu, Pandurang M. Kulkarni, Carol L. Gaich, Mayme Wong, Leo PlouffeJr.Jr. & John L. Stock. (2007) Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 40:4, pages 843-851.
Crossref
Crossref
FELICIA COSMAN & ROBERT LINDSAY. 2007. Treatment of the Postmenopausal Woman. Treatment of the Postmenopausal Woman
837
845
.
Taosheng ChenXu Feng. (2006) Cell-Based Assay Strategy for Identification of Motif-Specific RANK Signaling Pathway Inhibitors. ASSAY and Drug Development Technologies 4:4, pages 473-482.
Crossref
Crossref
Li Yuming, Zhang Zhongzhi, Deng Xiuling & Chen Lulu. (2005) Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. Journal of Huazhong University of Science and Technology [Medical Sciences] 25:5, pages 527-529.
Crossref
Crossref
Ira Pande & David J. Hosking. (2005) Oral antiresorptive therapy. Current Rheumatology Reports 7:1, pages 71-77.
Crossref
Crossref
Ira Pande & David J. Hosking. (2004) Oral antiresorptive therapy. Current Osteoporosis Reports 2:4, pages 116-122.
Crossref
Crossref
Ira Pande & David J. Hosking. (2004) Oral antiresorptive therapy. Current Osteoporosis Reports 2:4, pages 116-122.
Crossref
Crossref
Laura D. Carbone, Michael C. Nevitt, Kathryn Wildy, Karen D. Barrow, Fran Harris, David Felson, Charles Peterfy, Marjolein Visser, Tamara B. Harris, Benjamin W. E. Wang & Stephen B. Kritchevsky. (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis & Rheumatism 50:11, pages 3516-3525.
Crossref
Crossref